Domoprednate, a new nonhalogenated topical steroid: comparison to hydrocortisone butyrate.

Author(s): Schmidt H, Hjorth N, Holm P

Affiliation(s): Department of Dermatology and Venerology, Odense University Hospital, Denmark.

Publication date & source: 1987, Dermatologica., 175(3):145-7.

Publication type: Clinical Trial; Randomized Controlled Trial

Thirty-nine patients with mainly psoriasis vulgaris and atopic dermatitis were treated for 4 weeks with 0.1% domoprednate and hydrocortisone butyrate ointment according to a right-left, randomized design. Various assessments of efficacy only revealed marginal, but statistically insignificant differences. Patients' preferences for one of the two treatment favored domoprednate in 20 cases and hydrocortisone butyrate in 12 cases; 6 cases were ties (p greater than 0.2). The efficacy of domoprednate, a new, nonhalogenated topical steroid, is evidently at least of the same order as that of the hydrocortisone butyrate, and the tolerance of the two ointments is equally good.